Jurg Oehen

Part of Bristol Myers Squibb Co., Celgene Europe Ltd. is a British company that engages in research and development in pharmaceutical products. The company is based in Middlesex, UK.

Part of Bristol Myers Squibb Co., Celgene UK Holdings Ltd. functions as an investment holding company. The company is based in London, UK.

Part of Bristol Myers Squibb Co., Celgene UK Manufacturing (II) Ltd. functions as an investment holding company. The company is based in London, UK.

Part of Bristol Myers Squibb Co., Celgene UK Manufacturing Ltd. functions as an investment holding company. The company is based in London, UK.

Celgene Ltd. engages in the development of human pharmaceuticals and agrochemicals. It focuses on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. The company was founded on June 2, 2015 and is headquartered in Uxbridge, the United Kingdom.

Delinia, Inc. operates as a biotechnology company that develops novel therapeutics for the treatment of autoimmune diseases. Its main program is a molecule that potentiates and expands Regulatory T Cells, powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis. Tregs are critically important immune regulatory cells in the path physiology of cancer and autoimmune disease. Delinia was founded by Michael Rosenblum and Jeffrey Greve in 2015 and is headquartered in Summit, NJ.